21:34 , Sep 29, 2017 |  BC Week In Review  |  Clinical News

Medivir reports Phase IIa data of MIV-711 for OA

Medivir AB (SSE:MVIR B) reported top-line data showing that MIV-711 slowed the degenerative effects of moderate osteoarthritis (OA) on both bone and cartilage of the knee in the Phase IIa MIV-711-201 trial. The company said...
20:52 , Sep 26, 2017 |  BC Extra  |  Clinical News

Medivir rises on Phase IIa OA data

Medivir AB (SSE:MVIR B) gained SEK14.75 (25%) to SEK74.75 on Tuesday after reporting that MIV-711 slowed the degenerative effects of moderate osteoarthritis on both bone and cartilage of the knee in the Phase IIa MIV-711-201...
12:26 , Jun 22, 2017 |  BC Week In Review  |  Clinical News

Medivir continues extension study of MIV-711 in knee OA

An IDMC recommended continuation of a Phase IIa extension study of MIV-711 from Medivir AB (SSE:MVIR B) in 50 patients with moderate knee osteoarthritis (OA). The open-label, international extension is evaluating the safety of once-daily...
00:03 , Dec 9, 2016 |  BC Week In Review  |  Clinical News

MIV-711: Ph IIa MIV-711-201 ongoing

An IDMC recommended continuation for the third time the double-blind, placebo-controlled, European Phase IIa MIV-711-201 trial of oral MIV-711 based on safety data from the first 150 patients with knee joint OA who completed 3...
17:59 , Nov 2, 2016 |  BC Week In Review  |  Clinical News

MIV-711: Ph IIa completed enrollment

Medivir completed enrollment of 244 patients with knee joint OA in the double-blind, placebo-controlled, European Phase IIa MIV-711-201 trial evaluating 100 and 200 mg oral MIV-711 once daily for 6 months. Medivir AB (SSE:MVIR B),...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Company News

Medivir cancer news

Medivir AB Medivir will reduce headcount by 30 (25%) to about 90 and focus its pipeline exclusively on cancer. Cuts will come from the early research organization and administrative and commercial support functions. Medivir said...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

MIV-711: Phase IIa ongoing

An IDMC recommended continuation of the double-blind, placebo-controlled, European Phase IIa MIV-711-201 trial of oral MIV-711 based on safety data from 50 patients with knee joint OA who completed 3 months of treatment. The trial...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

Odanacatib: Development discontinued

Merck discontinued development of odanacatib after an independent adjudication and analysis of major adverse cardiovascular events confirmed an increased risk of stroke with the compound. Merck previously reported data from the double-blind, international Phase III...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Medivir deal

Medivir will split into two independent companies, one focused on R&D and one housing the company’s commercial products. The company expects to complete the division by year end. Medivir’s marketed products include HCV treatment Olysio...
07:00 , Sep 2, 2016 |  BC Extra  |  Company News

Merck discontinuing odanacatib

Merck & Co. Inc. (NYSE:MRK) said it is discontinuing development of odanacatib (formerly MK-0822 ) and will not seek regulatory approval of the cathepsin K inhibitor, which had completed Phase III testing for osteoporosis. The...